Compare AbbVie Inc (ABBV) vs Aptiv PLC (APTV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Aptiv PLC — how do they compare? AbbVie Inc trades at $254.06 (market cap $449.91B), while Aptiv PLC trades at $56.77 (market cap $12.45B). The key difference: AbbVie Inc is far larger — about 36.1× Aptiv PLC's market cap, and AbbVie Inc pays a 2.72% dividend while Aptiv PLC pays none. Which is the better fit depends on your goals.
| ABBV | APTV | |
|---|---|---|
Market Cap | $449.91B | $12.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $76.82 |
52-Week Low | $184.85 | $52.57 |
Enterprise Value | $513.38B | $19.17B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
APTV trades at $58.85, down 0.07% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.71, exceeding expectations of $1.62. Revenue for 2025 reached $20.40B with a net income margin of 1.77%. Analyst consensus is strongly bullish with a $80.67 price target, though technical indicators show selling pressure with support at $58.
The outlook remains mixed: strong analyst support and solid cash flow trends contrast with narrow profit margins and bearish technicals. Key risks include margin compression and high debt levels, but institutional sentiment suggests potential upside if earnings momentum continues through Q2 results on August 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →
